Drugs / FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU), Treprizumab, Tiggio capsule (S-1)
FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU), Treprizumab, Tiggio capsule (S-1)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04886193 | Apr 2021 → May 2022 | gastric cancer | Guangdong Provincial Hospital of Traditional Chinese Medicine | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU), Treprizumab, Tiggio capsule (S-1) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04886193 ↗ |
| Action | Inhibit | “toripalimab (an anti-PD-1 monoclonal antibody)” PMID 41206442 ↗ Nov 2025 |
| Modality | Monoclonal antibody | “toripalimab (an anti-PD-1 monoclonal antibody)” PMID 41206442 ↗ Nov 2025 |